Compositions and methods for t-cell activation comprising gm-csf and tumor antigen fusion proteins
CA 2241373 C · Owner: Ruegg, Curtis Landon · Inventors: Wu, Hongyu; Laus, Reiner; Ruegg, Curtis Landon
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed are therapeutic compositions and methods for inducing cytotoxic T cell responses in vitro and in vivo. The therapeutic compositions consist of antigen presenting cells activated by contact with a polypeptide complex constructed by joining together a dendritic cell-binding protein and a polypeptide antigen. Also disclosed are expression vectors and systems for producing the polypeptide complexes.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 23, 1996 and granted April 9, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 23, 2016.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 23, 2018.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.